The Life Sciences sector— biotechnologies, pharmaceuticals and biomedical technologies— is one of the most promising high-tech areas and could become a real driver for growth and overall development for Italy and its economy.
But only if an ecosystem favorable to innovation is created, one that removes obstacles and mechanisms that create distortion, and guarantees an integrated and coherent approach throughout the entire process of basic research, pre-clinical development and clinical development … up through the point at which the treatment is made available to patients, with recognition of the innovation that has become a tangible product.
An ecosystem that makes it possible to progress from scientific excellence to the creation of value, and which allows Italy to compete on a global scale in one of the sectors on which the future of our planet will be based.
A Scientific Committee, made up of internationally renowned experts, has overseen and actively contributed to this project: Alberto Mantovani (Scientific Director of the Istituto Clinico Humanitas), Francesco Granata (Executive in Residence at Warburg Pincus and Chairman of Circassia, UK) and Gianni Gromo (Partner of Versant Ventures, primary fund focusing on the HealthCare sector, and Scientific Advisor for two Israeli university funds: Integra -Yissum/ Hebrew University- e Momentum Fund - Ramot / Tel Aviv University).
The following paper sums up the issues and reflections that emerged during the Advisory Board and project meetings which took place between May and September 2016.